{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"75.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"85.0","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"description":"Time from first dose to first onset of transfusion independence ≥ 84 days.","dispersionType":"Full Range","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEDIAN","populationDescription":"ITT Population (all randomized participants regardless of whether or not the participant received treatment) who were RBC-TI \\>= 12 Weeks (Week 1-24) responders","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24","title":"Time to Red Blood Cell Transfusion Independence (RBC-TI) ≥ 12 Weeks (84 Days)","type":"SECONDARY","unitOfMeasure":"Days"}